A federal jury in California sided with medical tech company Masimo in its suit alleging that the Apple Watch infringed on its patent covering low-power pulse oximeter features. The victory hinged on the definition of the term “patient monitor,” which Apple argued only applied to devices that provided continuous monitoring, while the Apple Watch’s blood oxygen features only kick in after 10 minutes of inactivity. This case is separate from the one working its way through the ITC.